The European Medicines Agency (EMA) has published a summary of its Pharmacovigilance Risk Assessment Committee (PRAC) meeting held earlier this month.
To read the highlights and access more information on PRAC recommendations, Article 31 referrals and ongoing signal evaluations, please click here.